JP2017501172A - サバイビン指向性癌ワクチン治療 - Google Patents

サバイビン指向性癌ワクチン治療 Download PDF

Info

Publication number
JP2017501172A
JP2017501172A JP2016540693A JP2016540693A JP2017501172A JP 2017501172 A JP2017501172 A JP 2017501172A JP 2016540693 A JP2016540693 A JP 2016540693A JP 2016540693 A JP2016540693 A JP 2016540693A JP 2017501172 A JP2017501172 A JP 2017501172A
Authority
JP
Japan
Prior art keywords
survivin
cleaved
dotap
present
gluconoylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016540693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501172A5 (cg-RX-API-DMAC7.html
Inventor
ガイスラー，ジーモン
ボニフォルテ，パトリツィア
プラッシュケ，イェルク
ヴァイガンツ，マルクス
ジェーケル，シュテファン
ケルナー，ローラント
リジオク，トーマス
ミュラー−ポンパラ，ディルク
ハンス，ケネス
Original Assignee
メルク パテント ゲーエムベーハー
メルク パテント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク パテント ゲーエムベーハー, メルク パテント ゲーエムベーハー filed Critical メルク パテント ゲーエムベーハー
Publication of JP2017501172A publication Critical patent/JP2017501172A/ja
Publication of JP2017501172A5 publication Critical patent/JP2017501172A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016540693A 2013-12-16 2014-12-16 サバイビン指向性癌ワクチン治療 Pending JP2017501172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005831 2013-12-16
EP13005831.6 2013-12-16
PCT/EP2014/003384 WO2015090572A1 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Publications (2)

Publication Number Publication Date
JP2017501172A true JP2017501172A (ja) 2017-01-12
JP2017501172A5 JP2017501172A5 (cg-RX-API-DMAC7.html) 2017-12-28

Family

ID=49884863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540693A Pending JP2017501172A (ja) 2013-12-16 2014-12-16 サバイビン指向性癌ワクチン治療

Country Status (8)

Country Link
US (1) US20160279213A1 (cg-RX-API-DMAC7.html)
EP (1) EP3083663A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017501172A (cg-RX-API-DMAC7.html)
CN (1) CN105873941A (cg-RX-API-DMAC7.html)
AU (1) AU2014365888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2933705A1 (cg-RX-API-DMAC7.html)
IL (1) IL246299A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015090572A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023092178A (ja) * 2021-12-21 2023-07-03 株式会社アビー 細胞凍結保存液、及び細胞凍結方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA2940018C (en) * 2014-02-19 2018-12-04 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
CN109125741B (zh) * 2018-08-13 2022-02-11 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111983240B (zh) * 2020-08-27 2023-11-21 天津大学 一种产气荚膜梭菌α毒素可视化检测的方法
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
JP2011518170A (ja) * 2008-04-17 2011-06-23 ピーディーエス バイオテクノロジー コーポレイション カチオン性脂質の鏡像異性体による免疫応答の刺激

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736587B2 (en) * 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
JP2011518170A (ja) * 2008-04-17 2011-06-23 ピーディーエス バイオテクノロジー コーポレイション カチオン性脂質の鏡像異性体による免疫応答の刺激

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 74, no. 4, JPN6018041854, 2008, pages 950 - 958, ISSN: 0003905478 *
BIOCHEMISTRY, JPN6018041853, 2005, pages 44, ISSN: 0004036116 *
PNAS, vol. 101, no. 29, JPN6018041856, 2004, pages 10697 - 10702, ISSN: 0004036118 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023092178A (ja) * 2021-12-21 2023-07-03 株式会社アビー 細胞凍結保存液、及び細胞凍結方法
JP7318983B2 (ja) 2021-12-21 2023-08-01 株式会社アビー 細胞凍結保存液、及び細胞凍結方法

Also Published As

Publication number Publication date
CA2933705A1 (en) 2015-06-25
WO2015090572A1 (en) 2015-06-25
CN105873941A (zh) 2016-08-17
IL246299A0 (en) 2016-07-31
EP3083663A1 (en) 2016-10-26
AU2014365888A1 (en) 2016-07-28
AU2014365888B2 (en) 2018-12-06
US20160279213A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
AU2014365888B2 (en) Survivin-directed cancer vaccine therapy
US10729766B2 (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
Wu et al. CASTING: a potent supramolecular strategy to cytosolically deliver STING agonist for cancer immunotherapy and SARS-CoV-2 vaccination
KR102264820B1 (ko) 지질과 리포좀의 안정된 제제
EP3140320B1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US20090035360A1 (en) Lyophilised antigen composition
EP2292258A1 (en) Multiepitope vaccine for Her2/neu-associated cancers
JP2020533340A (ja) サポニンを含むリポソーム製剤および使用方法
JP7082110B2 (ja) アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
JP2024520477A (ja) ペプチドに基づくネオ抗原ワクチンの多成分化学組成物
KR102375057B1 (ko) Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물
KR20210052924A (ko) 작은 지질 나노 입자 및 이를 포함하는 암 백신
US20250302975A1 (en) Methods and compositions for agonising tlr3
JP2012523847A (ja) Ｎｇｅｐ抗原の免疫原性エピトープ
JP2018070629A (ja) がんの処置におけるサバイビンワクチンの有効性を向上させるための方法
HK40041061A (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
HK40004722A (en) Rna formulation for immunotherapy
HK40004722B (en) Rna formulation for immunotherapy
HK1220914B (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
HK1196071A (en) Mucinous glycoprotein(muc-1) vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190520